达普司他在中国上市了吗?好购买吗？

Daprostat is a new drug used to treat renal anemia and has received widespread international attention in recent years. The drug has not yet been officially launched in China, and patients cannot purchase it through regular channels. Since it is not included in the national medical insurance directory, its accessibility and economic burden have also become the focus of attention. This article will conduct a detailed analysis of the listing status, purchase difficulty, and medical insurance coverage status of daprestat in China.

Is dapostat available on the market in China

As of now, it has not been approved for marketing by the National Medical Products Administration (NMPA) in China. Although the drug has been maturely used abroad and has shown good efficacy and safety, it is still in the clinical research or approval stage in China.

It has been widely used abroad

Daprostat has been used for many years in Japan, Europe and the United States and other countries. It is mainly used to treat anemia caused by chronic kidney disease. Its oral dosage form is more convenient than traditional injection drugs and improves patient compliance.

There are no formal sales channels in China

Daprestat is currently not available in regular domestic hospitals and pharmacies as all registration procedures have not been completed. Some patients obtain drugs through overseas medical service institutions or special import channels, but this involves certain legal and safety risks.

Daprostat has not yet officially entered the market in China, and patients who want to use it still need to wait for its approval for marketing.

Is daplostat easy to buy?

Since it is not officially launched in China, the ways to obtain daplostat are extremely limited. Even if there are special needs, it is difficult to obtain them through legal and compliant means.

There are certain risks in purchasing drugs overseas

Some patients choose to purchase daprostat from Japan, Europe and other places through overseas drug purchasing platforms or personal channels. This type of method lacks supervision, making it difficult to distinguish the authenticity of drugs, and transportation and storage conditions may also affect the efficacy of the drugs.

Medical institutions do not currently provide this drug

Currently, daprostat is not sold in large domestic hospitals and chain pharmacies. Doctors can only choose approved similar drugs when prescribing, such as erythropoietin (EPO) and its analogs.

Daplostat is not easy to purchase at this stage, especially for ordinary patients, the threshold for obtaining it is high.

Is daprostat included in the national medical insurance?

Since it has not been approved for marketing in China, daprostat has naturally not been included in the national basic medical insurance, work injury insurance and maternity insurance drug catalog. This means that even if the patient is able to obtain the drug, he or she must bear the entire cost out of pocket.

It is expensive and limits its use

According to overseas market data, the monthly treatment cost of daprostat is relatively high, and long-term use puts great pressure on the family economy. Without access to the medical insurance system, most patients will find it unaffordable.

Reimbursement access takes time to advance

For new drugs to enter the reimbursement catalog, they usually need to first complete domestic marketing approval, and then go through multiple rounds of evaluation and negotiation. If dapostat is approved in the future, it will need to go through a longer medical insurance access cycle.

Alternative drugs guarantee basic treatment

Currently, a variety of drugs for the treatment of renal anemia have been included in the scope of medical insurance reimbursement in China, such as EPO preparations, iron supplements, etc., which can meet the basic treatment needs of patients to a certain extent.

Daprostat is currently neither on the medical insurance list nor affordable, making it difficult to become an optional treatment option for the public in the short term.